Fortesta
PreclinicalSmall molecule
Endo PharmaceuticalsFortesta is one of 17 small molecule programs targeting Hypogonadism. It is currently in Preclinical.
1
Indications
2
Total Trials
1
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
16 competitors in Hypogonadism
#DrugCompanyPhaseTrials
1Estrace
Novo NordiskApproved
Victoza
Novo NordiskApproved
Andriol
AAuxilium
Approved
Jatenzo
GGrupo Espanol de Tumores Neuroendocrinos
Approved
Arimidex
IIstituto Clinico Humanitas
Approved
Trelstar
OOncoVerity, Inc.
Approved
Delatestryl
AAntares Pharma Inc.
Approved
Orgovyx
Sumitomo Pharma America, Inc.Approved
Clomid
EMD SeronoApproved
Depo-Testosterone
AAzurity Pharmaceuticals
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Fortesta. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company